Workshop Overview Leadership Hotel and Travel Registration Program Agenda
Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Committee has reconvened to review state of the art technologies, identify current hurdles to further success and to make recommendations to the field.
Topics being addressed by individual working groups include:
The Immune Biomarkers Committee reconvened on May 16–17 for a two-day workshop on critical next steps in the field, including:
The workshop was held back-to-back with a two-day workshop from the Cancer Immune Responsiveness Task Force on May 14–15. Click here for more information about the Immuno-Oncology Biomarkers: State of the Art workshop.
As a benefit for attending the 2018 Immuno-Oncology Biomarkers: State of the Art workshop, the Society for Immunotherapy of Cancer (SITC) provides enduring materials free of charge for the specific programs for which attendees were registered. Attendees of the 2018 Immuno-Oncology Biomarkers: State of the Art workshop can click here to access enduring materials.
If you are a SITC member, or member of the general public, but did not register to attend the 2018 Immuno-Oncology Biomarkers: State of the Art Workshop, the materials are available for purchase at the link below.
2018 Immuno-Oncology Biomarkers: State of the Art workshop enduring materials will become available free of charge for the following individuals on the following dates:
Presentations and video recordings are available based on permission from presenters.
In the video below, published by OncLive, watch as SITC President Dr. Lisa Butterfield discusses the Immune Biomarkers Committee.
View current and past committee members via the links below:
Validation of Biomarkers to Predict Response to Immunotherapy in Cancer (two-part white paper) Journal for ImmunoTherapy of Cancer, November 2016
Novel technologies and emerging biomarkers for personalized cancer immunotherapy Journal for ImmunoTherapy of Cancer, January 2016
Systematic evaluation of immune regulation and modulation Journal for ImmunoTherapy of Cancer, March 2017
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy Journal for ImmunoTherapy of Cancer, May 2017
Click here to view a complete list of current and past published Immune Monitoring Technology Primers in the Journal for ImmunoTherapy of Cancer (JITC).
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools – a compass in the land of biomarker discovery Journal of Translational Medicine, September 2011
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers Clinical Cancer Research, May 2011
Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force Journal of Translational Medicine, December 2010
A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" Journal of Translational Medicine, December 2008
Workshop on Cancer Biometrics: Identifying Biomarkers and Surrogates of Cancer in Patients Journal of Immunotherapy, March/April 2005
Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy Journal of Immunotherapy, March/April 2002
NCI/CCR and SITC co-sponsored a 2016 biomarkers meeting to review the state of the art, discuss current hurdles to further success, and consider recommendations to move the field forward.
The main goals were to provide updated information to a wide audience and solicit stakeholder participation in promoting successful immune biomarker research.
A report of this meeting was published in JITC in March 2017. Click here to read Immunotherapy biomarkers 2016: overcoming the barriers. Also, to learn more about the event and its schedule, click here.
Lisa H. Butterfield, PhD University of Pittsburgh
Mary L. Disis, MD University of Washington
Bernard A. Fox, PhD Earle A. Chiles Research Institute
David Kaufman, MD, PhDBill & Melinda Gates Medical Research Institute
Samir N. Khleif, MD Georgia Health Sciences
Raj K. Puri, MD, PhD U.S. Food and Drug Administration
Sara M. Krizan Society for Immunotherapy of Cancer (SITC)
John Alvarez, MD, PhDJanssen Research & Development, LLC
Tony Arulanandam, PhD, DVMNextPoint Therapeutics
Jason D. Barbour, PhDSimpatica Medicine, Inc.
Srabani Bhaumik, PhDRoche
Vincenzo Bronte, MDUniversity of Verona
Marcus O. Butler, MDPrincess Margaret Hospital/Ontario Cancer Institute
Michael A. Cannarile, PhDRoche Pharma Research & Early Development
Alessandra Cesano, MD, PhDNanoString Inc.
Raphael Clynes, MD, PhDXencor, Inc.
Madhav Dhodapkar, MDYale Cancer Center
Kevin K. Dobbin, PhDCollege of Public Health, UGA
Jerome Galon, PhDUniversite Pierre Et Marie Curie, Sorbonne Universites
Sacha Gnjatic, PhDIcahn School of Medicine at Mount Sinai
Bruno GomesRoche Pharma Research and Early Development
Tim F. Greten, MDNational Institutes of Health
Jean-Charles J. B. Grivel, PhDSidra Medical and Research Center
Leif Håkansson, MDUniversity of Lund
Brent A. Hanks, MD, PhDDuke University Medical Center
Alexandre Harari, PhDUniversity Hospital of Lausanne (CHUV)
Priti S. Hegde, PhDGenentech, Inc.
Siwen Hu-Lieskovan, MD, PhDUniversity of California Los Angeles
Sylvia Janetzki, MDZellNet Consulting, Inc
Michael D. Kalos, PhDJanssen Oncology
Vaios Karanikas, PhDRoche Innovation Center Zurich
Mohan Karkada, PhDWyss Institute for Biologically Inspired Engineering at Harvard Univversity
John M. Kirkwood, MDUPMC Hillman Cancer Center
Ilan Kirsch, MDAdaptive Biotechnologies Corp.
Thomas O. Kleen, PhDPrecision for Medicine
Yoshinobu Koguchi, MD, PhDEarle A. Chiles Research Institute, Providence Cancer Center
Beatrix Kotlan, PhDNational Institute of Oncology
Pia Kvistborg, PhDNetherlands Cancer Institute
Dominic W. Lai, MDAbbVie
Peter P. Lee, MDCity of Hope
Amanda W. Lund, PhDOregon Health & Science University
Cristina Maccalli, PhDSidra Medical and Research Department
Holden T. Maecker, PhDStanford University Medical Center
Francesco M. Marincola, MDRefuge Biotechnologies
Giuseppe V. Masucci, MD, PhDKarolinska Institutet
Howard L. McLeod, PharmDMoffitt Cancer Center
Elza Meeusen, PhDCancerProbe Pty Ltd
Aung Naing, MD, FACPUniversity of Texas MD Anderson Cancer Center
Ruslan D. Novosiadly, PhD, MDEli Lilly and Company
Raj K. Puri, MD, PhDFood and Drug Administration
Igor Puzanov, MD, MSCI, FACPRoswell Park Comprehensive Cancer Center
Laura Rosa Brunet, ScDRosa Brunet Consulting LTD
Sergio Rutella, MD, PhD, FRCPath
Senthamil R. Selvan, PhDBiomarker Strategies, LLC
Janet C. Siebert, MSCytoAnalytics
Tasha Sims, PhDRegeneron Pharmaceuticals, Inc.
Eric A. Singer, MD, MA, FACSRutgers Cancer Institute of New Jersey
Wenru Song, MD, PhDAstraZeneca
Edward C. Stack, PhDJounce Therapeutics
David F. Stroncek, MDNational Institutes of Health
Magdalena Thurin, PhDNational Institutes of Health
Giorgio Trinchieri, MDNational Cancer Institute
Nicholas Tschernia, MDUniversity of Rochester
Theresa L. Whiteside, PhDUniversity of Pittsburgh Cancer Institute
Jon M. Wigginton, MDMacroGenics, Inc.
Timothy L. Wyant, PhDCuris Inc
Jianda Yuan, MD, PhDDirector of Translational Immuno-Oncology Research
Yingdong Zhao, PhDNCI - Biometric Research Branch
Heinz Zwierzina, MDInnsbruck Medical University; Chair of the Cancer Drug Development Forum
Hello SITC community! I will appreciate any insights going forward for AML patients who have progressed after receiving allogeneic BMT and currently enrolled for treatment with Gilteritinib. Will such patients benefit from currently approved immunotherapies ...
This message was posted by a user wishing to remain anonymous Given that each cytokine degrades at different points in the media...while setting up a multiplex in vitro cytokine profiling assay, (with PBMCs post treatment) what is the best time point ...
Dear colleagues, Dear participants,
I would like to invite you to attend and participate actively in our
ISOBM (International Society of Oncology and BioMarkers) 2018 CONGRESS, to be held in Hamburg, Germany, on November 24 - 27, 2018. ...
Animal models have shown intestinal microbiota are crucial for therapeutic efficacy for CTLA4 blockade ( has decreased tumor size) and anti-PD1 psychotherapies.That the microbiome may be a target that can be modulated to enhance treatment responses. Theoretically, ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org